MX2020013166A - Dosificación y efecto del antagonista de c5a con la vasculitis asociada con anca. - Google Patents

Dosificación y efecto del antagonista de c5a con la vasculitis asociada con anca.

Info

Publication number
MX2020013166A
MX2020013166A MX2020013166A MX2020013166A MX2020013166A MX 2020013166 A MX2020013166 A MX 2020013166A MX 2020013166 A MX2020013166 A MX 2020013166A MX 2020013166 A MX2020013166 A MX 2020013166A MX 2020013166 A MX2020013166 A MX 2020013166A
Authority
MX
Mexico
Prior art keywords
anca
human
antagonist
dosing
effect
Prior art date
Application number
MX2020013166A
Other languages
English (en)
Inventor
Jun Deng
Petrus Bekker
Jan Hillson
Original Assignee
Chemocentryx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemocentryx Inc filed Critical Chemocentryx Inc
Publication of MX2020013166A publication Critical patent/MX2020013166A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente divulgación proporciona métodos para el tratamiento de la vasculitis asociada a ANCA en un ser humano que lo necesite, el método que comprende la administración al humano de una cantidad terapéuticamente efectiva de avacopan: (ver formula) o una sal farmacéuticamente aceptable del mismo, de modo que el nivel de factor del complemento en plasma Bb, C3a o C5a no cambia significativamente en el humano después del tratamiento.
MX2020013166A 2018-06-07 2019-06-06 Dosificación y efecto del antagonista de c5a con la vasculitis asociada con anca. MX2020013166A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862682013P 2018-06-07 2018-06-07
PCT/US2019/035758 WO2019236820A1 (en) 2018-06-07 2019-06-06 Dosing and effect of c5a antagonist with anca-associated vasculitis

Publications (1)

Publication Number Publication Date
MX2020013166A true MX2020013166A (es) 2021-03-29

Family

ID=68764799

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020013166A MX2020013166A (es) 2018-06-07 2019-06-06 Dosificación y efecto del antagonista de c5a con la vasculitis asociada con anca.

Country Status (14)

Country Link
US (2) US11191756B2 (es)
EP (1) EP3801519A4 (es)
JP (1) JP2021527062A (es)
KR (1) KR20210018906A (es)
CN (1) CN112423752A (es)
AU (1) AU2019282327A1 (es)
BR (1) BR112020024842A2 (es)
CA (1) CA3102403A1 (es)
CL (1) CL2020003171A1 (es)
IL (1) IL279188A (es)
MA (1) MA52808A (es)
MX (1) MX2020013166A (es)
SG (1) SG11202011961YA (es)
WO (1) WO2019236820A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113164403A (zh) 2018-11-30 2021-07-23 凯莫森特里克斯股份有限公司 胶囊制剂
AU2020380367A1 (en) 2019-11-08 2022-05-12 Chemocentryx, Inc. Salt forms of a complement component C5a receptor
US11603356B2 (en) 2019-11-08 2023-03-14 Chemocentryx, Inc. Amorphous form of a complement component C5a receptor

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1739078A1 (de) 2005-05-30 2007-01-03 Jerini AG C5a-Rezeptor-Antagonisten
WO2008079371A1 (en) * 2006-12-22 2008-07-03 Encysive Pharmaceuticals, Inc. Modulators of c3a receptor and methods of use thereof
EP2826791A3 (en) * 2008-02-20 2015-07-29 Novo Nordisk A/S Humanized anti-C5aR antibodies
US20110275639A1 (en) 2008-12-22 2011-11-10 Chemocentryx, Inc. C5aR ANTAGONISTS
SI2381778T1 (sl) 2008-12-22 2016-10-28 Chemocentryx, Inc. Antagonisti C5AR
DK2585064T3 (en) 2010-06-24 2017-07-24 Chemocentryx Inc C5aR antagonists
ES2926828T3 (es) 2014-09-29 2022-10-28 Chemocentryx Inc Procesos e intermedios en la preparación de antagonistas de C5aR
WO2016166357A2 (en) 2015-04-17 2016-10-20 The Provost, Fellows, Foundation Scholars, & The Other Members Of Board, Of The College Of The Holy & Undiv. Trinity Of Queen Elizabeth, Near Dublin Method and assay for diagnosing rapidly progressive glomerulonephritis in a subject
JP7121722B2 (ja) 2016-04-04 2022-08-18 ケモセントリックス，インコーポレイティド 可溶性Ｃ５ａＲアンタゴニスト
CA3078732A1 (en) * 2017-10-31 2019-05-09 Chemocentryx, Inc. C5ar inhibitor reduction of urinary scd163

Also Published As

Publication number Publication date
EP3801519A4 (en) 2022-03-30
JP2021527062A (ja) 2021-10-11
US20220296576A1 (en) 2022-09-22
WO2019236820A1 (en) 2019-12-12
MA52808A (fr) 2021-04-14
IL279188A (en) 2021-01-31
KR20210018906A (ko) 2021-02-18
CL2020003171A1 (es) 2021-06-04
SG11202011961YA (en) 2020-12-30
US11191756B2 (en) 2021-12-07
CN112423752A (zh) 2021-02-26
CA3102403A1 (en) 2019-12-12
BR112020024842A2 (pt) 2021-03-02
EP3801519A1 (en) 2021-04-14
US20190374524A1 (en) 2019-12-12
AU2019282327A1 (en) 2021-01-07

Similar Documents

Publication Publication Date Title
MX2023008453A (es) Metodos de tratamiento para el abuso de sustancias.
MX2021000071A (es) Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer.
MX2023000213A (es) Uso de dexmedetomidina sublingual para el tratamiento de la agitacion.
MX2020013166A (es) Dosificación y efecto del antagonista de c5a con la vasculitis asociada con anca.
MX2019013279A (es) Metodos de tratamiento del sindrome de doose utilizando fenfluramina.
PH12020551597A1 (en) Treatment of hidradenitis suppurativa using jak inhibitors
MX2018006674A (es) Tratamiento de cancer usando 2-desoxi-2-fluoro-l-fucosa en combinacion con un inhibidor del punto de control.
NZ739392A (en) Methods for treating hepcidin-mediated disorders
MX2021002321A (es) Nuevos metodos.
MX2023010064A (es) Un esteroide c21-n-pirazolilo 19-nor c3,3-disustituido, y metodos de uso del mismo.
MX2021002556A (es) Tratamiento del dolor postquirurgico.
MX2021002322A (es) Nuevos metodos.
MX2021013354A (es) Metodos para tratar y/o prevenir queratosis actinica.
MX2023000187A (es) Dosificacion de vibegron para el tratamiento de vejiga sobreactiva.
EP3991749A3 (en) A therapeutic agent for a tumor comprising an ido inhibitor administered in combination with an antibody
MY194448A (en) Short synthetic peptide for treating diseases and/or conditions related to angiogenesis
MX2018010223A (es) Terapia combinada para tratamiento de cancer de ovario.
MY186840A (en) Method for treating psoriasis patient which received anti-tnf-alpha antibody therapy
IL283324A (en) A process for the production of pharmaceutical dosage forms containing task-1 and task-3 channel inhibitors and their use in the treatment of respiratory disorders
EA202193276A1 (ru) Способы лечения холангиокарциномы
MX2018001684A (es) Metodo de curacion de heridas.
SG10201809673RA (en) Treatment of androgen deprivation therapy associated symptoms
MX2019014784A (es) Tratamiento para la migra?a.
IL282718A (en) Compounds for use in the treatment or prevention of pain, inflammation and/or autoimmune diseases
MX2020001217A (es) Metodos de tratamiento de sintomas de gastroparesia usando velusetrag.